Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-10-01-2001
Volume0
Issue 0

National Crisis Supercedes Coverage Debate

Author(s):

Jill Wechsler, Pharm Exec’s Washington Correspondent

Efforts to craft a Medicare pharmacy benefit may be sidelined by repercussions from the September attack.

Articles in this issue
National Crisis Supercedes Coverage Debate
PBMs: Merck-Medco in the Hot Seat
National Crisis Supercedes Coverage Debate
image4-686-1409031567502.gif
A Five-Year Forecast: Clear Seas Ahead?
Weak Bones, Strong Market
Weak Bones, Strong Market
Approvals: Novartis’ Silver Lining

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 23rd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 23rd 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 23rd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 23rd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 23rd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 23rd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor